Literature DB >> 16455650

Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate.

Alexei F Kisselev1, Alice Callard, Alfred L Goldberg.   

Abstract

The relative importance of the different proteolytic sites in mammalian proteasomes in protein degradation has not been studied systematically. Nevertheless, it is widely assumed that inhibition of the chymotrypsin-like site, the primary target of the proteasome inhibitors used in research and cancer therapy, reflects the degree of inhibition of protein breakdown. Here we demonstrate that selective inactivation of the chymotrypsin-like site reduced degradation of model proteins by pure 26 S proteasomes by only 11-50% and decreased only slightly the breakdown of proteins in HeLa cells. Inactivation of the caspase-like site decreased breakdown of model proteins by 12-22% and of the trypsin-like site by 3-35%. The relative contributions of these different sites depended on the protein substrate, and the importance of the trypsin-like sites depended on the substrate's content of basic residues. Simultaneous inhibition of the chymotrypsin-like and the caspase- or trypsin-like sites was needed to reduce degradation by >50%. Thus, 1) all three types of active sites contribute significantly to protein breakdown, 2) their relative importance varies widely with the substrate, 3) assaying the chymotrypsin-like activity overestimates the actual reduction in protein degradation, and 4) inhibition of multiple sites is required to markedly decrease proteolysis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16455650     DOI: 10.1074/jbc.M509043200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  144 in total

1.  Blm10 protein promotes proteasomal substrate turnover by an active gating mechanism.

Authors:  Thomas Dange; David Smith; Tahel Noy; Philipp C Rommel; Lukas Jurzitza; Radames J B Cordero; Anne Legendre; Daniel Finley; Alfred L Goldberg; Marion Schmidt
Journal:  J Biol Chem       Date:  2011-10-24       Impact factor: 5.157

2.  The origin of proteasome-inhibitor resistant HLA class I peptidomes: a study with HLA-A*68:01.

Authors:  Noel García-Medel; Alejandro Sanz-Bravo; Eilon Barnea; Arie Admon; José A López de Castro
Journal:  Mol Cell Proteomics       Date:  2011-10-03       Impact factor: 5.911

3.  A panel of subunit-selective activity-based proteasome probes.

Authors:  Martijn Verdoes; Lianne I Willems; Wouter A van der Linden; Boudewijn A Duivenvoorden; Gijsbert A van der Marel; Bogdan I Florea; Alexei F Kisselev; Herman S Overkleeft
Journal:  Org Biomol Chem       Date:  2010-05-06       Impact factor: 3.876

4.  Nature of pharmacophore influences active site specificity of proteasome inhibitors.

Authors:  Michael Screen; Matthew Britton; Sondra L Downey; Martijn Verdoes; Mathias J Voges; Annet E M Blom; Paul P Geurink; Martijn D P Risseeuw; Bogdan I Florea; Wouter A van der Linden; Alexandre A Pletnev; Herman S Overkleeft; Alexei F Kisselev
Journal:  J Biol Chem       Date:  2010-10-11       Impact factor: 5.157

5.  Peptidomic analysis of HEK293T cells: effect of the proteasome inhibitor epoxomicin on intracellular peptides.

Authors:  Lloyd D Fricker; Julia S Gelman; Leandro M Castro; Fabio C Gozzo; Emer S Ferro
Journal:  J Proteome Res       Date:  2012-02-16       Impact factor: 4.466

6.  Inhibitors of the proteasome stimulate the epithelial sodium channel (ENaC) through SGK1 and mimic the effect of aldosterone.

Authors:  Morag K Mansley; Christoph Korbmacher; Marko Bertog
Journal:  Pflugers Arch       Date:  2017-08-31       Impact factor: 3.657

7.  Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation-induced osteoporosis.

Authors:  Abhishek Chandra; Luqiang Wang; Tiffany Young; Leilei Zhong; Wei-Ju Tseng; Michael A Levine; Keith Cengel; X Sherry Liu; Yejia Zhang; Robert J Pignolo; Ling Qin
Journal:  FASEB J       Date:  2017-08-31       Impact factor: 5.191

8.  Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites.

Authors:  Paul P Geurink; Wouter A van der Linden; Anne C Mirabella; Nerea Gallastegui; Gerjan de Bruin; Annet E M Blom; Mathias J Voges; Elliot D Mock; Bogdan I Florea; Gijs A van der Marel; Christoph Driessen; Mario van der Stelt; Michael Groll; Herman S Overkleeft; Alexei F Kisselev
Journal:  J Med Chem       Date:  2013-01-28       Impact factor: 7.446

9.  Autoubiquitination of the 26S proteasome on Rpn13 regulates breakdown of ubiquitin conjugates.

Authors:  Henrike C Besche; Zhe Sha; Nikolay V Kukushkin; Andreas Peth; Eva-Maria Hock; Woong Kim; Steven Gygi; Juan A Gutierrez; Hua Liao; Lawrence Dick; Alfred L Goldberg
Journal:  EMBO J       Date:  2014-05-08       Impact factor: 11.598

10.  PPAR-gamma AF-2 domain functions as a component of a ubiquitin-dependent degradation signal.

Authors:  Gail E Kilroy; Xiaoying Zhang; Z Elizabeth Floyd
Journal:  Obesity (Silver Spring)       Date:  2009-01-15       Impact factor: 5.002

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.